NCT06923826View on ClinicalTrials.gov

Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

April 30, 2030

Study Completion Date

April 30, 2030

Conditions
Salivary Gland CancerThyroid Cancer
Interventions
DRUG

Sacituzumab govitecan

Day 1 and Day 8: Sacituzumab Govitecan will be administered at the dose of 10 mg/kg via intravenous infusion.

Trial Locations (1)

119074

RECRUITING

National University Cancer Institute Singapore, Singapore

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

National University Hospital, Singapore

OTHER